Market Insight: Brainstorm Cell Therapeutics, Inc. (BCLI)’s Notable Drop, Closing at 0.34

Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

In the latest session, Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) closed at $0.34 down -3.65% from its previous closing price of $0.35. In other words, the price has decreased by -$3.65 from its previous closing price. On the day, 0.14 million shares were traded. BCLI stock price reached its highest trading level at $0.3659 during the session, while it also had its lowest trading level at $0.3303.

Ratios:

For a deeper understanding of Brainstorm Cell Therapeutics, Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.18 and its Current Ratio is at 0.18.

Maxim Group reiterated its Buy rating for the stock on December 19, 2016, while the target price for the stock was revised from $5 to $6.

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 01 ’23 when Lindborg Stacy bought 11,500 shares for $1.77 per share. The transaction valued at 20,402 led to the insider holds 181,500 shares of the business.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCLI now has a Market Capitalization of 23995562 and an Enterprise Value of 24337572.

Stock Price History:

The Beta on a monthly basis for BCLI is 0.36, which has changed by -0.83 over the last 52 weeks, in comparison to a change of 0.25510752 over the same period for the S&P500. Over the past 52 weeks, BCLI has reached a high of $2.13, while it has fallen to a 52-week low of $0.13. The 50-Day Moving Average of the stock is -26.03%, while the 200-Day Moving Average is calculated to be -9.51%.

Shares Statistics:

For the past three months, BCLI has traded an average of 781.83K shares per day and 551640 over the past ten days. A total of 79.58M shares are outstanding, with a floating share count of 71.15M. Insiders hold about 10.59% of the company’s shares, while institutions hold 5.08% stake in the company. Shares short for BCLI as of 1718323200 were 890588 with a Short Ratio of 1.14, compared to 1715731200 on 1414121. Therefore, it implies a Short% of Shares Outstanding of 890588 and a Short% of Float of 1.3200001.

Most Popular